Cyted Health, known as a leader in the field of gastrointestinal (GI) molecular diagnostics, has completed the first close of its Series B financing round, raising $44 million. This funding is set to play a crucial role in supporting Cyted’s ongoing expansion efforts in the United States, a market that presents significant opportunities for growth in advanced diagnostics.
The Series B round was spearheaded by EQT Life Sciences, which approached the investment through its dedicated EQT Health Economics strategy. Joining in this endeavor as co-leads were Advent Life Sciences and the British Business Bank. They are providing support alongside existing investors, such as Morningside and BGF.
Cyted plans to leverage this substantial funding to accelerate the growth of its innovative diagnostics platform in the US. Additionally, the company aims to build on its existing successes in the UK, where its technology has already made a significant impact. This funding will also enable Cyted to expand its portfolio of advanced diagnostic tests, thereby enhancing its range of services for patients and healthcare providers.
One of the standout features of Cyted’s technology is EndoSign, a groundbreaking device that has received FDA 510(k) clearance. This device enables the minimally invasive collection of esophageal cells, a critical step in diagnosing various esophageal conditions. Alongside this, Cyted offers sophisticated biomarker molecular testing that plays a crucial role in accurately and efficiently detecting these conditions.
The success of Cyted’s technology is evidenced by its significant uptake within the UK’s National Health Service. To date, the company has performed over 35,000 tests, establishing a robust portfolio of peer-reviewed publications that showcase not only the technology’s effectiveness but also its high level of patient acceptability. This is especially important given the harsh reality that esophageal cancer is one of the deadliest types of cancer globally, with a survival rate hovering around just 20%. Early and accurate detection is crucial, and Cyted is positioned to make a real difference in this area.
Founded by a team of leading experts from the University of Cambridge, Cyted is pioneering advancements in the healthcare field. The company focuses on developing minimally invasive methods for cell collection, paired with proprietary biomarker discovery technologies. Their mission is to transform the way pre-cancerous, cancerous, and inflammatory esophageal conditions are detected, ultimately improving patient outcomes and survival rates.
The Series B funding comes at a notable time as Cyted has recently launched its DETECT-ME clinical validation study. This ambitious study, which has been actively enrolling patients across multiple sites in the US since March 2025, is designed to validate the clinical performance of Cyted’s latest assays and molecular tests for detecting esophageal conditions using the EndoSign device. By gathering data from this study, Cyted hopes to contribute valuable insights that will not only affirm the effectiveness of their technology but will also pave the way for broader adoption in clinical settings.
With this new round of funding, the company is well-equipped to make significant strides towards improving the lives of patients facing serious esophageal health challenges.
KEY QUOTES:
“This Series B financing marks a defining moment for Cyted as we continue to deepen our commitment to detecting esophageal diseases earlier. This investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio.”
Marcel Gehrung, CEO and Co-founder of Cyted Health
“Cyted is strongly positioned to redefine the standard of care in upper GI diagnostics worldwide.Its minimally invasive diagnostics platform is the standout innovation to capture this significant market opportunity, and we’re delighted to add the company to our portfolio.”
Bruno Holthof, Partner at EQT Life Sciences
“Cyted has demonstrated a rare combination of clinical innovation, patient-centered delivery, and commercial execution with an impressive foundation in the UK. We’re proud to support its next phase of growth.”
Kaasim Mahmood, General Partner at Advent Life Sciences
“Cyted is an excellent example of the kind of high-impact business we aim to back. Their innovation has the potential to transform early cancer detection and create lasting health outcomes both in the UK and globally.”
Carmine Circelli, Director, Life Sciences at British Business Bank
*”I am pleased to see the British Business Bank back Cyted – a company whose growth demonstrates the ability of our universities to turn ***world-class life sciences research into successful commercial opportunities with the potential to improve people’s lives. Life sciences form a critical part of this Government’s ambitions for both the economy and healthcare – and through our Life Sciences Sector Plan, we will continue to support the industry to even greater success.”
Science Minister Lord Vallance
